EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated Neurodegeneration

Chitra Subramanian, Matthew W Frank, Rajaa Sukhun, Christopher E Henry, Anna Wade, Mallory E Harden, Satish Rao, Rajendra Tangallapally, Mi-Kyung Yun, Stephen W White, Richard E Lee iD, Uma Sinha und 2 weitere

The Journal of Pharmacology and Experimental Therapeutics · 2024-01 · 388 (1) · 171-180

DOI: 10.1124/jpet.123.001919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-01. Verfasst von Chitra Subramanian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Infectious Diseases (C.S., M.W.F., C.O.R., S.J.), Chemical Biology and Therapeutics (R.T., R.E.L.), Structural Biology (M.-K.Y., S.W.W…. Hauptthemen laut MEDLINE: Pantothenate Kinase-Associated Neurodegeneration. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pantothenate kinase-associated neurodegeneration (PKAN) is characterized by a motor disorder with combinations of dystonia, parkinsonism, and spasticity, leading to premature death. PKAN is caused by mutations in the PANK2 gene that result in loss or reduction of PANK2 protein function. PANK2 is one of three kinases that initiate and regulate coenzyme A biosynthesis from vitamin B5, and the ability of BBP-671, an allosteric activator of pantothenate kinases, to enter the brain and elevate coenzyme A was investigated. The metabolic stability, protein binding, and membrane permeability of BBP-671 all suggest that it has the physical properties required to cross the blood-brain barrier. BBP-671 was detected in plasma, liver, cerebrospinal fluid, and brain following oral administration in rodents, demonstrating the ability of BBP-671 to penetrate the brain. The pharmacokinetic and pharmacodynamic properties of orally administered BBP-671 evaluated in cannulated rats showed that coenzyme A (CoA) concentrations were elevated in blood, liver, and brain. BBP-671 elevation of whole-blood acetyl-CoA served as a peripheral pharmacodynamic marker and provided a suitable method to assess target engagement. BBP-671 treatment elevated brain coenzyme A concentrations and improved movement and body weight in a PKAN mouse model. Thus, BBP-671 crosses the blood-brain barrier to correct the brain CoA deficiency in a PKAN mouse model, resulting in improved locomotion and survival and providing a preclinical foundation for the development of BBP-671 as a potential treatment of PKAN. SIGNIFICANCE STATEMENT: The blood-brain barrier represents a major hurdle for drugs targeting brain metabolism. This work describes the pharmacokinetic/pharmacodynamic properties of BBP-671, a pantothenate kinase activator. BBP-671 crosses the blood-brain barrier to correct the neuron-specific coenzyme A (CoA) deficiency and improve motor function in a mouse model of pantothenate kinase-associated neurodegeneration. The central role of CoA and acetyl-CoA in intermediary metabolism suggests that pantothenate kinase activators may be useful in modifying neurological metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pantothenate Kinase-Associated NeurodegenerationMiceAnimalsRatsAcetyl Coenzyme ACoenzyme ADisease Models, AnimalPhosphotransferases (Alcohol Group Acceptor)Brain

Substanzen

pantothenate kinaseAcetyl Coenzyme ACoenzyme APhosphotransferases (Alcohol Group Acceptor)

Autor:innen und Institutionen

  • Departments of Infectious Diseases (C.S., M.W.F., C.O.R., S.J.), Chemical Biology and Therapeutics (R.T., R.E.L.), Structural Biology (M.-K.Y., S.W.W.), and St. Jude Graduate School of Biomedical Sciences (S.W.W.), St.…

ORCID-Profile: Richard E Lee, Charles O Rock

Zitieren

APA

Subramanian, C., Frank, M. W., Sukhun, R., Henry, C. E., Wade, A., Harden, M. E., Rao, S., Tangallapally, R., Yun, M. K., White, S. W., Lee, R. E., Sinha, U., Rock, C. O., & Jackowski, S. (2024). Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated Neurodegeneration. The Journal of Pharmacology and Experimental Therapeutics, 388(1), 171-180. https://doi.org/10.1124/jpet.123.001919

Vancouver

Subramanian C, Frank MW, Sukhun R, Henry CE, Wade A, Harden ME, et al. Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated Neurodegeneration. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(1):171-180. doi:10.1124/jpet.123.001919

BibTeX
@article{Subramanian2024,
  author = {Subramanian, Chitra and Frank, Matthew W and Sukhun, Rajaa and Henry, Christopher E and Wade, Anna and Harden, Mallory E and Rao, Satish and Tangallapally, Rajendra and Yun, Mi-Kyung and White, Stephen W and Lee, Richard E and Sinha, Uma and Rock, Charles O and Jackowski, Suzanne},
  title = {Pantothenate Kinase Activation Restores Brain Coenzyme A in a Mouse Model of Pantothenate Kinase-Associated Neurodegeneration},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  volume = {388},
  number = {1},
  pages = {171--180},
  doi = {10.1124/jpet.123.001919}
}
Kostenlos starten →